Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Sequana Medical NV
< Previous
1
2
3
Next >
Sequana Medical announces results of Extraordinary General Meeting of Shareholders
November 10, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces additional alfapump data supporting strong and durable clinical profile; PMA on track for year-end submission
October 19, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces initial positive data from MOJAVE, a US Phase 1/2a study of DSR® 2.0 for treatment of heart failure through breaking vicious cycle of cardiorenal syndrome
October 18, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces H1 2023 results and provides business update
September 14, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical Notice of 2023 Half-year Results and Business Update
September 06, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces first patient enrolled in MOJAVE, a US randomized controlled Phase 1/2a study of DSR® 2.0 for treatment of congestive heart failure
July 10, 2023
From
Sequana Medical NV
Via
GlobeNewswire
1,000th alfapump® implant completed
July 06, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces results of Special General Meeting of Shareholders
June 26, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces additional data on safety, quality of life and survival from North American pivotal alfapump® study (POSEIDON)
June 21, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Additional data from North American pivotal alfapump® study (POSEIDON) will be presented at EASL Congress 2023
June 19, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical wins Best Technology Award for alfapump® at European Mediscience Awards
June 16, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces Special General Meeting of Shareholders on 26 June 2023
May 26, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces results of Annual General Meeting of Shareholders
May 25, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Transparency Notifications from Shareholders
May 15, 2023
From
Sequana Medical NV
Via
GlobeNewswire
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
May 10, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces FDA clearance of IND application for DSR® 2.0 for treatment of congestive heart failure
May 02, 2023
From
Sequana Medical NV
Via
GlobeNewswire
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
April 27, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces submission of Investigational New Drug (IND) application for DSR® 2.0 for treatment of congestive heart failure
April 03, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces additional patents for DSR® in China and the United States
March 22, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces positive results from CHIHUAHUA, Phase 1 clinical trial of second-generation DSR product for congestive heart failure
March 01, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces results of Extraordinary General Meeting of Shareholders
February 10, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces 2022 Full Year Results and 2023 Outlook
February 09, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Transparency Notifications from Shareholders
February 09, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure
February 08, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical Notice of 2022 Full Year Results and Business Update
February 02, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces grant of additional DSR® patent in United States
February 01, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces Extraordinary General Meeting of Shareholders on 10 February 2023
January 11, 2023
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON
November 15, 2022
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical to present at Jefferies London Healthcare Conference
November 08, 2022
From
Sequana Medical NV
Via
GlobeNewswire
Sequana Medical announces positive top-line results from the North American pivotal alfapump® study (POSEIDON)
October 25, 2022
From
Sequana Medical NV
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today